StockData
Apyx Medical Corp logo

Apyx Medical Corp (APYX) stock

APYXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/3035% above fair value
$2.89−0.11 (-3.67%)

Close on Nov 12, 2026Market cap $121.74MP/E –Yield –

Earnings

Apyx Medical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$14.00M
+8.5% on a year earlier
EPS, Q3 FY2026
-$0.04
-$0.05 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Apyx Medical's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 9, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$14.00M+8.5%-$0.04Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours$13.90M+21.9%-$0.07Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$12.50M+33.0%-$0.05Release
Q4 FY2025ended Dec 31, 2025Mar 10, 2026before the open$19.20M+35.2%-$0.03Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$12.90M+12.2%-$0.05Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$11.40M-5.8%-$0.09Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$9.40M-7.8%-$0.10Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025before the open$14.20M-3.4%-$0.12Release
Q3 FY2024ended Sep 30, 2024Nov 8, 2024before the open$11.50M-4.2%-$0.14Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$12.10M-11.0%-$0.19Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$10.20M-15.7%-$0.22Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Apyx Medical's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$59.00M – $60.00M$57.50M – $58.50MRaisedNov 5, 2026
Total revenueFY2026$59.00M – $60.00M$59.00M – $60.00MRaisedAug 6, 2026
gross marginsFY202663% – 65%–NewNov 5, 2026
OEM revenueFY2026$5.00M–LoweredNov 5, 2026
operating expensesFY2026$41.00M – $42.50M–RaisedNov 5, 2026
operating expensesFY2026$45.00M$45.00MReaffirmedAug 6, 2026
Surgical Aesthetics revenueFY2026$54.00M – $55.00M–NewNov 5, 2026

Guidance vs results

The last range Apyx Medical gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$50.50M – $52.50M$52.90MΣ4QAbove range

Guidance history

Every forecast Apyx Medical put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026gross marginsFY202663% – 65%New
Nov 5, 2026Surgical Aesthetics revenueFY2026$54.00M – $55.00MNew
Nov 5, 2026OEM revenueFY2026$5.00MLowered
Nov 5, 2026operating expensesFY2026$41.00M – $42.50MRaised
Nov 5, 2026Total revenueFY2026$59.00M – $60.00MRaised
Aug 6, 2026operating expensesFY2026$45.00MReaffirmed
Aug 6, 2026Total revenueFY2026$59.00M – $60.00MRaised
Aug 6, 2026Surgical Aesthetics revenueFY2026$54.00M – $55.00MLowered
Aug 6, 2026OEM revenueFY2026$5.00MLowered
May 7, 2026operating expensesFY2026$45.00MNew
May 7, 2026Total revenueFY2026$59.00M – $60.00MNew
May 7, 2026Surgical Aesthetics revenueFY2026$54.00M – $55.00MLowered
May 7, 2026OEM revenueFY2026$5.00MLowered
Mar 10, 2026Total revenueFY2026$57.50M – $58.50MNew
Nov 6, 2025operating expensesFY2025$40.00MNew
Nov 6, 2025Total revenueFY2025$50.50M – $52.50MNew
Nov 6, 2025Surgical Aesthetics revenueFY2025$43.00M – $45.00MLowered
Nov 6, 2025OEM revenueFY2025$7.50MLowered
Aug 7, 2025Total revenueFY2025$50.00M – $52.00MRaised
Aug 7, 2025Advanced Energy revenueFY2025$42.00M – $44.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Apyx Medical filed with the SEC as exhibits to Form 8-K or 6-K

  1. Apyx Medical Corporation Reports Third Quarter 2026 Financial Results
    Results
  2. Apyx Medical Announces New Clinical Study Demonstrating Renuvion ® ’s Impact on Skin Quality
    News
  3. Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
    Results
  4. New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli ® and Renuvion ®
    News
  5. Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion ® Used In Combination With Liposuction
    News
  6. Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System ™
    News
  7. Apyx Medical Corporation Reports First Quarter 2026 Financial Results
    Results
  8. Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
    Results
  9. Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
    Results
  10. Medical Corporation Announces Proposed Public Offering of Common Stock
    News
  11. Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock
    News
  12. Apyx Medical Corporation Reports Third Quarter 2025 Financial Results
    Results
  13. Apyx Medical Corporation Reports Second Quarter 2025 Financial Results
    Results
  14. Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System ™
    News
  15. Apyx Medical Corporation Reports First Quarter 2025 Financial Results
    Results

See a number that looks wrong?